2025-11-15 - Analysis Report
Okay, here's a report analyzing Recursion Pharmaceuticals (RXRX), incorporating the provided data and news.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance Relative to S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -33.31%
*   **VOO Cumulative Return:** 40.59%
*   **Divergence:**
    *   Current: -60.1%
    *   Range: (Max: 84.1, Min: -64.3)
    *   Relative Divergence: 2.8%

**Analysis:** RXRX has significantly underperformed the S&P 500 over the analyzed period. The current divergence is -60.1%, and the relative divergence of 2.8% suggests it's near the bottom of its historical divergence range compared to VOO. This indicates substantial underperformance relative to the market benchmark.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
| ---------- | ------ | ----- | ------ | ---- | ------ |
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.1 | 5.1    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1  | 3.5    |
| 2023-2025  | 9.0%   | 80.0% | -54.0% | 0.1  | 2.2    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate (CAGR) has decreased over time, from 22.0% in 2021-2023 to 9.0% in 2023-2025. This suggests a decelerating growth trend.
*   **MDD:**  The Maximum Drawdown (MDD) remains consistently high around 80-81%, indicating significant risk and volatility in the stock's price.
*   **Alpha:**  Alpha has decreased significantly from a positive 26.0% to a negative -54.0%. This shows a decline in the stock's ability to generate excess returns relative to its benchmark.
*   **Beta:**  Beta values are close to zero, indicating low systematic risk or correlation with the market.
*   **Cap(B):**  The market capitalization has decreased from $5.1 billion to $2.2 billion over the analyzed periods, reflecting a loss of investor confidence and market value.

**2. Recent Price Action**

*   **Current Price:** $4.14
*   **Previous Close:** $4.33
*   **Change:** -4.39%
*   **5-Day Moving Average:** 4.468
*   **20-Day Moving Average:** 5.334
*   **60-Day Moving Average:** 5.1632

**Analysis:** The stock price is currently below all three moving averages (5, 20, and 60 days), indicating a short-term to medium-term downtrend. The recent price decrease of -4.39% suggests a significant negative movement in the last trading session.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 7.81 (Oversold)
*   **PPO:** -3.0662
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90)"
*   **Recent (20-Day) Relative Divergence Change:** -6.4 (Negative - Short-term Decline)
*   **Expected Return:** -163.1%

**Analysis:** The RSI of 7.81 indicates a heavily oversold condition, which can sometimes precede a price rebound.  The PPO (Percentage Price Oscillator) is negative, supporting the downtrend. The MRI suggests a medium investment recommendation. The Hybrid Signal recommends a full investment of available cash, however, the extremely negative expected return of -163.1% is a major cause for concern, implying substantial long-term underperformance compared to the S&P 500.  The recent large negative change in price (-4.39%) highlights heightened volatility.

**4. Recent News & Significant Events**

*   **Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock (Motley Fool)**: Suggests alternative AI stocks may be more promising.
*   **Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships? (Simply Wall St.)**: Focuses on the potential impact of the new CEO.
*   **Recursion Pharmaceuticals (RXRX): Annual Losses Widen 35.2% Despite 30.1% Forecast Revenue Growth (Simply Wall St.)**: Highlights increasing losses despite revenue growth.
*   **RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)**: Reports a narrower-than-expected loss but declining revenues.
*   **Recursion Pharmaceuticals Names Najat Khan as Chief Executive and President (MT Newswires)**: Announces a new CEO.
*   **Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)**: Reports a loss and missed revenue estimates.

**Analysis:** The news is mixed.  The appointment of a new CEO could be a positive catalyst. However, the widening losses and missed revenue estimates are concerning. The article suggesting alternative AI stocks is also a negative signal.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (~Hold)
*   **Opinions:** 6
*   **Target Price (avg/high/low):** 6.30 / 10.00 / 3.00
*   **Recent Rating Changes:** No significant changes indicated (→)

**Analysis:** The analyst consensus is a "Hold" rating. The average target price of $6.30 suggests potential upside from the current price, but the range is wide ($3.00 - $10.00), indicating uncertainty among analysts.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
| ---------- | ----- | ------------ |
| 2025-11-05 | -0.36 | 0.01 B$      |
| 2025-08-05 | -0.41 | 0.02 B$      |
| 2025-05-05 | -0.5  | 0.01 B$      |
| 2024-11-06 | -0.34 | 0.03 B$      |
| 2025-11-05 | -0.34 | 0.03 B$      |

**Analysis:** Recursion Pharmaceuticals has consistently reported losses per share (EPS).  Revenue has been inconsistent, with some quarters showing higher revenue than others. Recent EPS and Revenue do not show meaningful improvement.

**6. Financial Information**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-09-30   | $0.00B    | -194.74%      |
| 2025-06-30   | $0.02B    | -5.54%        |
| 2025-03-31   | $0.01B    | -47.31%       |
| 2024-12-31   | $0.00B    | -183.62%      |
| 2024-09-30   | $0.03B    | 53.69%        |

| Quarter      | Equity    | ROE       |
| ------------ | --------- | --------- |
| 2025-09-30   | $1.05B    | -15.50%   |
| 2025-06-30   | $0.92B    | -18.70%   |
| 2025-03-31   | $0.93B    | -21.68%   |
| 2024-12-31   | $1.03B    | -17.29%   |
| 2024-09-30   | $0.52B    | -18.27%   |

**Analysis:**  Revenue is volatile and sometimes near zero. Profit margins are generally negative, indicating the company is spending significantly more than it earns. Return on Equity (ROE) is also consistently negative, indicating the company is not generating profits from shareholders' investments.  While equity is relatively high, the negative ROE is a concern.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) presents a high-risk investment opportunity.

*   **Negative Factors:** Significant underperformance compared to the S&P 500, decreasing CAGR and Alpha, high MDD, widening losses, negative profit margins and ROE, a large negative expected return, recent price decline below key moving averages, mixed news with concerns about profitability, and an alternative AI stock suggestion.
*   **Potential Positive Factors:** Oversold RSI indicating a potential short-term rebound, new CEO appointment potentially driving future growth, medium investment recommendation from MRI, and a "Hold" analyst consensus with potential upside based on target prices.
*   **Recommendation:** Given the significant underperformance, financial losses, and negative expected return, investors should exercise extreme caution. The stock may be suitable only for those with a very high risk tolerance and a belief in the company's long-term potential related to AI in drug discovery.  Close monitoring of financial performance and news is crucial.
